TY  - GEN
AU  - Delgado-Fernandez, Marcial
AU  - Garcia-Gemar, Gracia Mar
AU  - Fuentes-Lopez, Ana
AU  - Munoz-Perez, Manuel Isidro
AU  - Oyonarte-Gomez, Salvador
AU  - Ruiz-Garcia, Ignacio
AU  - Martin-Carmona, Jessica
AU  - Sanz-Canovas, Jaime
AU  - Castano-Carracedo, Manuel Aangel
AU  - Reguera-Iglesias, Jose Maria
AU  - Ruiz-Mesa, Juan Diego
PY  - 2022
DO  - 10.1016/j.eimc.2021.01.013
SN  - 0213-005X
UR  - https://hdl.handle.net/10668/26025
T2  - Enfermedades infecciosas y microbiologia clinica
AB  - Patients lacking humoral response have been suggested to develop a less severe COVID-19, but there are some reports with a prolonged, relapsing or deadly course. From April 2020, there is growing evidence on the benefits of COVID-19 convalescent...
LA  - en
PB  - Ediciones doyma s a
KW  - Covid-19
KW  - Convalescent plasma
KW  - Humoral immunodeficiency
KW  - Rituximab
KW  - Obinutuzumab
KW  - Coronavirus disease 2019
KW  - Liver-transplant recipients
KW  - Rituximab
KW  - Sars-cov-2
KW  - Therapy
KW  - Antibodies
KW  - Mechanism
KW  - Outcomes
TI  - Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature
TY  - review
VL  - 40
ER  -